# Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

> **NCT03120949** · PHASE3 · COMPLETED · sponsor: **R-Pharm International, LLC** · enrollment: 2106 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Olokizumab 64 mg SC q4w
- **DRUG:** Olokizumab 64 mg SC q2w
- **DRUG:** Concomitant treatment

## Key facts

- **NCT ID:** NCT03120949
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-04
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 2106 (ACTUAL)
- **Last updated:** 2023-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03120949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03120949, "Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03120949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*